OxyKart in Clinical Context
OxyKart is Earkart's oxymetazoline hydrochloride nasal preparation, containing oxymetazoline hydrochloride 0.05% w/v in a buffered aqueous solution. It is positioned for the short-term relief of nasal congestion — the blocked-nose sensation that commonly accompanies colds, dust and pollution exposure, and seasonal changes.
Nasal congestion arises when the blood vessels of the nasal lining become dilated and the tissues swell, narrowing the nasal passages. Topical decongestants such as oxymetazoline act locally on the nasal mucosa and are an established short-term option in congestion care. The emphasis on short-term matters: the label directs that oxymetazoline-containing nasal preparations should not be used for longer than 10 consecutive days, and that a treatment-free period of several days should precede any repeated use.
This duration discipline is precisely why physician guidance is central to responsible congestion care. Prolonged or unsupervised use of topical decongestants is a well-recognised clinical concern, and OxyKart carries the Schedule H caution on its label. Earkart presents OxyKart for use as directed by a physician, and this page is intended as product information for healthcare professionals, chemists and distribution partners rather than as self-medication guidance.
Within the Earkart ENT portfolio, OxyKart complements FlutiKart and FlutiKart OX in the allergy and congestion space, while NasoKart isotonic saline supports daily nasal hygiene. The range is manufactured at a WHO-GMP certified facility, reflecting the division's specialist-led, compliance-first approach.
